China (Mainland)
Premiumsupplier 
Tirasemtiv(CK-2017357) CAS NO.1005491-05-3
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram
- Product Details
Keywords
- Tirasemtiv(CK-2017357)
- tiraseMtiv (CK-2017357);6-ethynyl-1-(pentan-3-yl)-1H-iMidazo[4,5-b]pyrazin-2-ol;TiraseMtiv;1-(1-Ethylpropyl)-6-ethynyl-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-2-one;CK 2017357;Tirasemtiv 1-(1-Ethylpropyl
- 1005491-05-3
Quick Details
- ProName: Tirasemtiv(CK-2017357)
- CasNo: 1005491-05-3
- Molecular Formula: C12H14N4O
- Appearance: white solid
- Application: CAS:1005491-05-3;
- DeliveryTime: 3 months
- PackAge: 100g,500g,1kg,25kg/drum
- Port: shang hai
- ProductionCapacity: 1000 Gram/Month
- Purity: 98%
- Storage: Dry seal
- Transportation: shipping
- LimitNum: 100 Gram
Superiority
We are committed to provide excellence in researching, manufacturing and drug discovery process.
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.
Details
Tirasemtiv(CK 2017357) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction.
IC50 value:
Target: Troponin activator
Binding selectively to the fast-skeletal-troponin complex, CK-2017357 slows the rate of calcium release from troponin C and sensitizes muscle to calcium. CK-2017357 increases the production of muscle force in situ at sub-maximal nerve stimulation rates. sensitization of the fast-skeletal-troponin complex to calcium improves muscle force and grip strength immediately after administration of single doses of CK-2017357 in a model of the neuromuscular disease myasthenia gravis [1]. single doses of 250 mg and 500 mg of CK-2017357 were safe and well tolerated by patients with ALS [2]. Mice receiving a high dose of tirasemtiv had significantly higher muscle fiber cross-sectional area and respiratory response to CO stimulation at 16 weeks than mice on low dose or placebo [3].